KESHAV
EUR 823.33
1,800+ vendidosFarmacia fisica em Hong Kong, 100% de autenticidade garantida
Elafibranor received accelerated approval in the United States in June 2024.
10000 em stock
Indicated for adults with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid or cannot tolerate it.
Elafibranor Como funciona Como funciona ，
2 ， ， / (2.1) 80 mg， (2.2) 2.1 IQIRVO IQIRVO [ Precaucoes (5.1)] IQIRVO ， [ Precaucoes (5.3)， (8.1, 8.3)] 2.2 IQIRVO 80 mg， [ (12.3)] 2.3 IQIRVO 4 4 ， [ (7.2)]
5 Precaucoes IQIRVO ， (CPK) ， IQIRVO 5.1 IQIRVO ， 5.2
11 GFT1007 PPAR pH 1.2 6.8 ， pH 7.5 ， DMSO ， C₂₂H₂₄O₄S， 384.49 g/mol， 2-(2,6- -4-{3-[4-( ) ]-3- -1- -1- } )-2- ， IQIRVO 80 mg ，
Indicated for adults with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid or cannot tolerate it.
2 ， ， / (2.1) 80 mg， (2.2) 2.1 IQIRVO IQIRVO [ Precaucoes (5.1)] IQIRVO ， [ Precaucoes (5.3)， (8.1, 8.3)] 2.2 IQIRVO 80 mg， [ (12.3)] 2.3 IQIRVO 4 4 ， [ (7.2)]
5 Precaucoes IQIRVO ， (CPK) ， IQIRVO 5.1 IQIRVO ， 5.2
8.1 ， IQIRVO ， elafibranor ， / ， IQIRVO ，
12 12.1 Como funciona GFT1007 PPAR ， PPAR-α PPAR-γ PPAR-δ ， PBC PPAR-α PPAR-δ ，PPAR-δ 21 FGF21 CYP7A1 ，CYP7A1 PPAR ，elafibranor GFT1007 PPAR-α EC50 46 nM 14 nM，Em 0.05 0.05
13 13.1 2 CD-1 ， elafibranor 1 3 10 30 mg/kg/ ， elafibranor GFT1007 AUC， 0.007 0.14 0.003 0.16 Sprague-Dawley ， elafibranor 10 mg/kg/ elafibranor GFT1007 AUC 0.36 ， 30 mg/kg/ elafibranor GFT1007 AUC 2.1 ，elafibranor
14 1 (NCT04526665) IQIRVO 161 (UDCA) (PBC) IQIRVO 80 mg (n=108) (n=53)， ， 52 ， UDCA (ALP) ≥ (ULN) 1.67 ， (TB) ≤ 2
Indicacoes
Indicated for adults with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid or cannot tolerate it.
Mecanismo de acao
Elafibranor Como funciona Como funciona ，
Dosagem
2 ， ， / (2.1) 80 mg， (2.2) 2.1 IQIRVO IQIRVO [ Precaucoes (5.1)] IQIRVO ， [ Precaucoes (5.3)， (8.1, 8.3)] 2.2 IQIRVO 80 mg， [ (12.3)] 2.3 IQIRVO 4 4 ， [ (7.2)]
Precaucoes
5 Precaucoes IQIRVO ， (CPK) ， IQIRVO 5.1 IQIRVO ， 5.2
